AtonRa Partners’s Intellia Therapeutics NTLA Stock Holding History

AtonRa Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$229K	Sell	7,502 -868	-10%	-$24.9K	0.46%	101
2023 Q3	$265K	Sell	8,370 -1,804	-18%	-$70K	0.56%	89
2023 Q2	$415K	Sell	10,174 -713	-7%	-$28.9K	0.64%	73
2023 Q1	$406K	Sell	10,887 -1,445	-12%	-$56.7K	0.59%	78
2022 Q4	$430K	Sell	12,332 -4,552	-27%	-$216K	0.55%	79
2022 Q3	$945K	Buy	16,884 +114	+0.7%	+$7.07K	0.93%	45
2022 Q2	$868K	Sell	16,770 -3,210	-16%	-$163K	0.8%	53
2022 Q1	$1.45M	Sell	19,980 -9,606	-32%	-$814K	0.79%	54
2021 Q4	$3.5M	Buy	29,586 +3,433	+13%	+$430K	1.22%	27
2021 Q3	$3.51M	Buy	26,153 +6,477	+33%	+$981K	1.17%	29
2021 Q2	$3.19M	Buy	19,676 +8,546	+77%	+$665K	1.17%	31
2021 Q1	$893K	Buy	+11,130	New	+$747K	0.4%	96

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AtonRa Partners's NTLA Position: Q4 2023 in Review

AtonRa Partners reduced its Intellia Therapeutics (NTLA) stake by 10% in Q4 2023, selling an estimated $24.9K and leaving 7,502 shares worth $229K. The position accounts for 0.46% of the portfolio, ranked #101.

AtonRa Partners first reported a position in NTLA in Q1 2021 and has held it in 12 quarters since. The position peaked at $3.51M in Q3 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

AtonRa Partners held 7,502 shares of Intellia Therapeutics worth $229K as of Q4 2023.
AtonRa Partners sold 868 Intellia Therapeutics shares in Q4 2023, an estimated $24.9K.
Intellia Therapeutics made up 0.46% of AtonRa Partners's portfolio in Q4 2023, its #101 holding.
AtonRa Partners first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 12 quarters since.
AtonRa Partners's Intellia Therapeutics position peaked at $3.51M in Q3 2021.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.